Vance W Berger

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Does the Prentice criterion validate surrogate endpoints?
    Vance W Berger
    Biometry Research Group, National Cancer Institute at University of Maryland Baltimore County, National National Institutes of Health
    Stat Med 23:1571-8. 2004
  2. ncbi request reprint Refining the assessment of the sensitivity and specificity of diagnostic tests, with applications to prostate cancer screening and non-small cell lung cancer staging
    Vance W Berger
    Biometry Research Group, National Cancer Institute NIH, Executive Plaza North, Suite 3131, 6130 Executive Boulevard, MSC 7354, Bethesda, MD 20892 7354, USA
    Rev Panam Salud Publica 18:64-70. 2005
  3. ncbi request reprint Quantifying the magnitude of baseline covariate imbalances resulting from selection bias in randomized clinical trials
    Vance W Berger
    Biometry Research Group, National Cancer Institute, Executive Plaza North, Suite 3131, 6130 Executive Boulevard, MSC 7354, Bethesda, MD 20892 7354, USA
    Biom J 47:119-27; discussion 128-39. 2005
  4. ncbi request reprint Nonparametric adjustment techniques for binary covariates
    Vance W Berger
    National Cancer Institute, 6130 Executive Boulevard, MSC 7354, Bethesda, MD 20892 7354, USA
    Biom J 47:199-205. 2005
  5. ncbi request reprint Improving the information content of categorical clinical trial endpoints
    Vance W Berger
    Biometry Research Group, National Cancer Institute, Bethesda, MD 20892 7354, USA
    Control Clin Trials 23:502-14. 2002
  6. ncbi request reprint Evaluating research training outcomes: experience from the cancer prevention fellowship program at the National Cancer Institute
    Graca M Dores
    Office of Preventive Oncology, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7361, USA
    Acad Med 81:535-41. 2006
  7. ncbi request reprint On improving research methodology in clinical trials
    Vance W Berger
    National Cancer Institute, University of Maryland, Baltimore, MD, USA
    Stat Methods Med Res 17:231-42. 2008
  8. ncbi request reprint A review of methods for ensuring the comparability of comparison groups in randomized clinical trials
    Vance W Berger
    National Cancer Institute, Biometry Research Group, Bethesda, MD 20892 7354, USA
    Rev Recent Clin Trials 1:81-6. 2006
  9. pmc A general framework for the evaluation of clinical trial quality
    Vance W Berger
    National Institutes of Health National Cancer Institute, 6130 Executive Boulevard, MSC 7354, Bethesda, MD 20892 7354 USA
    Rev Recent Clin Trials 4:79-88. 2009
  10. ncbi request reprint Analysis of trichotomous pharmaceutical endpoints
    Vance W Berger
    Biometry Research Group, National Cancer Institute, University of Maryland, Baltimore County, Maryland, USA
    J Biopharm Stat 15:739-45. 2005

Detail Information

Publications26

  1. ncbi request reprint Does the Prentice criterion validate surrogate endpoints?
    Vance W Berger
    Biometry Research Group, National Cancer Institute at University of Maryland Baltimore County, National National Institutes of Health
    Stat Med 23:1571-8. 2004
    ....
  2. ncbi request reprint Refining the assessment of the sensitivity and specificity of diagnostic tests, with applications to prostate cancer screening and non-small cell lung cancer staging
    Vance W Berger
    Biometry Research Group, National Cancer Institute NIH, Executive Plaza North, Suite 3131, 6130 Executive Boulevard, MSC 7354, Bethesda, MD 20892 7354, USA
    Rev Panam Salud Publica 18:64-70. 2005
  3. ncbi request reprint Quantifying the magnitude of baseline covariate imbalances resulting from selection bias in randomized clinical trials
    Vance W Berger
    Biometry Research Group, National Cancer Institute, Executive Plaza North, Suite 3131, 6130 Executive Boulevard, MSC 7354, Bethesda, MD 20892 7354, USA
    Biom J 47:119-27; discussion 128-39. 2005
    ..We find that a binary covariate can, on average, be up to 50% unbalanced by third-order selection bias...
  4. ncbi request reprint Nonparametric adjustment techniques for binary covariates
    Vance W Berger
    National Cancer Institute, 6130 Executive Boulevard, MSC 7354, Bethesda, MD 20892 7354, USA
    Biom J 47:199-205. 2005
    ..Each of these approaches is nonparametric and exact, and so it is the precise reason for adjusting that should dictate which would be used in any given situation...
  5. ncbi request reprint Improving the information content of categorical clinical trial endpoints
    Vance W Berger
    Biometry Research Group, National Cancer Institute, Bethesda, MD 20892 7354, USA
    Control Clin Trials 23:502-14. 2002
    ..We also point out that using composite endpoints allows sponsors the most discretion in selecting their primary between-group statistical analysis. We illustrate these ideas with examples from a variety of therapeutic areas...
  6. ncbi request reprint Evaluating research training outcomes: experience from the cancer prevention fellowship program at the National Cancer Institute
    Graca M Dores
    Office of Preventive Oncology, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7361, USA
    Acad Med 81:535-41. 2006
    ....
  7. ncbi request reprint On improving research methodology in clinical trials
    Vance W Berger
    National Cancer Institute, University of Maryland, Baltimore, MD, USA
    Stat Methods Med Res 17:231-42. 2008
    ....
  8. ncbi request reprint A review of methods for ensuring the comparability of comparison groups in randomized clinical trials
    Vance W Berger
    National Cancer Institute, Biometry Research Group, Bethesda, MD 20892 7354, USA
    Rev Recent Clin Trials 1:81-6. 2006
    ....
  9. pmc A general framework for the evaluation of clinical trial quality
    Vance W Berger
    National Institutes of Health National Cancer Institute, 6130 Executive Boulevard, MSC 7354, Bethesda, MD 20892 7354 USA
    Rev Recent Clin Trials 4:79-88. 2009
    ..We will demonstrate that current evaluations fall well short of these ideals...
  10. ncbi request reprint Analysis of trichotomous pharmaceutical endpoints
    Vance W Berger
    Biometry Research Group, National Cancer Institute, University of Maryland, Baltimore County, Maryland, USA
    J Biopharm Stat 15:739-45. 2005
    ..The purpose of this paper is to fill this gap by offering an objective approach for parameter selection, and to provide real data examples to illustrate the use of this objective approach...
  11. ncbi request reprint The reverse propensity score to detect selection bias and correct for baseline imbalances
    Vance W Berger
    National Cancer Institute, EPN, Bethesda, MD 20892 7354, USA
    Stat Med 24:2777-87. 2005
    ..We demonstrate how the reverse propensity score allows for both detection of and correction for selection bias, or systematic baseline imbalances...
  12. doi request reprint Sensitivity designs for preventing bias replication in randomized clinical trials
    Vance W Berger
    NIH, Bethesda, MD 20892 7354, USA
    Stat Methods Med Res 19:415-24. 2010
    ..This of course makes the attribution of the results to the treatments much more plausible and makes the findings much more robust to violations of assumptions...
  13. ncbi request reprint On the generation and ownership of alpha in medical studies
    Vance W Berger
    National Cancer Institute, University of Maryland Baltimore County, Biometry Research Group, Executive Plaza North, Suite 3131, 6130 Executive Boulevard, MSC 7354, Bethesda, MD 20892 7354, USA
    Control Clin Trials 25:613-9. 2004
    ..05 to work with. We will address these inconsistencies, and ask more generally where alpha comes from, how it can be generated, and under what conditions it should be one-tailed or two-tailed...
  14. ncbi request reprint Ensuring the comparability of comparison groups: is randomization enough?
    Vance W Berger
    National Cancer Institute, EPN, Suite 3131, 6130 Executive Boulevard, MSC 7354, Bethesda, MD 20892 7354, USA
    Control Clin Trials 25:515-24. 2004
    ..Nevertheless, there have been a few published reports that contain descriptions of either this type of selection bias or indicators that it may have occurred...
  15. ncbi request reprint Direct effect on validity of response run-in selection in clinical trials
    Vance W Berger
    National Cancer Institute, Bethesda, MD 20892, USA
    Control Clin Trials 24:156-66. 2003
    ....
  16. ncbi request reprint Minimizing predictability while retaining balance through the use of less restrictive randomization procedures
    Vance W Berger
    National Cancer Institute, EPN, Suite 3131, 6130 Executive Boulevard, MSC 7354, Bethesda, MD 20892 7354, USA
    Stat Med 22:3017-28. 2003
    ..This feature makes the maximal procedure more resistant to selection bias than the randomized block procedure is...
  17. ncbi request reprint When can a clinical trial be called 'randomized'?
    Vance W Berger
    National Cancer Institute, EPN, Suite 3131, 6130 Executive Boulevard, MSC 7354, Bethesda, MD 20892 7354, USA
    Vaccine 21:468-72. 2003
    ..After reviewing the benefits of randomization, paying particular attention to the specific aspects of randomization that confer each benefit, we will explore the issue of what constitutes a randomized study...
  18. ncbi request reprint The analysis of stratified 2 x 2 contingency tables
    Vance W Berger
    University of Maryland Baltimore County and National Cancer Institute, Executive Plaza North, Suite 3131, Bethesda, MD 20892 7354, USA
    Biom J 48:992-1007. 2006
    ..We develop novel tests that are analogous to the Smirnov, modified Smirnov, convex hull, and adaptive tests that have been proposed for ordered categorical data...
  19. ncbi request reprint Adjusting for observable selection bias in block randomized trials
    Anastasia Ivanova
    Department of Biostatistics, The University of North Carolina at Chapel Hill, NC 27599, USA
    Stat Med 24:1537-46. 2005
    ..The method allows not only testing for the presence of observable selection bias, but also testing for a difference in treatment effects, adjusting for possible selection bias...
  20. ncbi request reprint Varying the block size does not conceal the allocation
    Vance W Berger
    J Crit Care 21:229; author reply 229-30. 2006
  21. ncbi request reprint Misguided precedent is not a reason to use permuted blocks
    Vance W Berger
    Headache 46:1210-2. 2006
  22. ncbi request reprint Preventing fungal infections in chronic granulomatous disease
    Vance W Berger
    N Engl J Med 349:1190-1; author reply 1190-1. 2003
  23. ncbi request reprint Critical appraisal of individual trials?
    Vance W Berger
    Am J Gastroenterol 101:1156-7; author reply 1157. 2006
  24. ncbi request reprint Do not use blocked randomization
    Vance W Berger
    Headache 46:343; author reply 343-5. 2006
  25. pmc The Decameron of poor research
    Vance W Berger
    Biometry Research Group, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    BMJ 329:1436-40. 2004
  26. ncbi request reprint Response to Klassen et al: Missing data should be more heartily penalized
    Vance W Berger
    J Clin Epidemiol 59:759-60. 2006